Refine Your Results

Click below to filter your search results

"Breast Cancer"Undo
"Medications or Drugs"Undo

Search Results

Return to List
Results 1–3 of 3
Sort By: Relevance| Date| Title

Committee Opinion Number 738, June 2018

(Replaces Committee Opinion Number 663, June 2016)

Members Only


Committee Opinion Number 659, March 2016

(Reaffirmed 2018)

ABSTRACT: Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic-related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer are hormone sensitive, there are safety concerns about the use of local hormone therapy in women who currently have breast cancer or have a history of breast cancer. Nonhormonal approaches are t...


Committee Opinion Number 606, August 2014

(Reaffirmed 2016)

ABSTRACT: Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding, and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding emergently. Therapy in both situations should be tailored to the patient, her cancer diagnosis and treatment plan, and her desires for contraception and fertility. Options for menstrual suppression include combined hormonal contraceptives, progestin-only therapy, and gonadotropin-releasing hormone agoni...


American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188